Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$2.23 - $4.38 $230,622 - $452,970
-103,418 Reduced 54.71%
85,610 $199,000
Q1 2024

May 15, 2024

BUY
$2.92 - $5.63 $505,405 - $974,462
173,084 Added 1085.57%
189,028 $844,000
Q3 2023

Nov 14, 2023

BUY
$3.17 - $5.96 $50,542 - $95,026
15,944 New
15,944 $50,000
Q3 2022

Nov 14, 2022

SELL
$10.32 - $17.28 $877,385 - $1.47 Million
-85,018 Reduced 43.0%
112,701 $1.22 Million
Q2 2022

Aug 15, 2022

SELL
$6.78 - $12.28 $297,458 - $538,760
-43,873 Reduced 18.16%
197,719 $2.25 Million
Q1 2022

May 16, 2022

BUY
$7.65 - $15.29 $424,651 - $848,747
55,510 Added 29.83%
241,592 $2.2 Million
Q4 2021

Feb 14, 2022

BUY
$13.13 - $24.52 $1.67 Million - $3.12 Million
127,355 Added 216.86%
186,082 $2.78 Million
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $2.21 Million - $2.9 Million
-105,101 Reduced 64.15%
58,727 $1.51 Million
Q2 2021

Aug 16, 2021

BUY
$23.49 - $35.8 $1.94 Million - $2.96 Million
82,563 Added 101.6%
163,828 $4.27 Million
Q1 2021

May 17, 2021

SELL
$25.79 - $39.02 $1.35 Million - $2.05 Million
-52,476 Reduced 39.24%
81,265 $2.87 Million
Q4 2020

Feb 16, 2021

BUY
$25.24 - $43.45 $928,781 - $1.6 Million
36,798 Added 37.96%
133,741 $3.38 Million
Q3 2020

Nov 16, 2020

BUY
$32.38 - $44.96 $3.14 Million - $4.36 Million
96,943 New
96,943 $3.66 Million
Q1 2020

May 15, 2020

SELL
$18.22 - $28.25 $284,960 - $441,830
-15,640 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$24.82 - $31.4 $388,184 - $491,096
15,640 New
15,640 $406,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.